Astellas Pharma Inc. (ALPMY) News
Follow Astellas Pharma Inc. (ALPMY) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Astellas Secures Option for Audax DAX-044 in Deal Worth Up to $1.34 Billion
Astellas Pharma entered an exclusive option and license agreement for Audax Biosciences' DAX-04.
MNA | Oct 28, 2026, 08:35 AM UTC
L
Pfizer, Astellas announces FDA approval of PADCEV plus Keytruda in MIBC
Pfizer (PFE) and Astellas Pharma (ALPMY) announced that the U.S. Food and Drug Administration has approved PADCEV, a Nectin-4 directed antibody-drug conjugate, plus the PD-1 inhibitor, Keytruda or Keytruda QLEX as neoadj
COMMODITIES | Jul 10, 2026, 03:26 PM UTC
H
SGMO Files Chapter 11
Sangamo Therapeutics files for Chapter 11 bankruptcy protection and agrees to sell assets to Eli Lilly and Astellas Pharma
EQUITY | Jun 23, 2026, 05:48 PM UTC